MCF-7: the first hormone-responsive breast cancer cell line.
about
MicroRNA-27a Indirectly Regulates Estrogen Receptor {alpha} Expression and Hormone Responsiveness in MCF-7 Breast Cancer CellsEstrogenic potential of certain pyrethroid compounds in the MCF-7 human breast carcinoma cell lineMSRE-PCR for analysis of gene-specific DNA methylationThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceAssessment of cellular estrogenic activity based on estrogen receptor-mediated reduction of soluble-form catechol-O-methyltransferase (COMT) expression in an ELISA-based systemSystematic Quality Control Analysis of LINCS DataAcoustophoretic sorting of viable mammalian cells in a microfluidic deviceThe immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor αMurine models of breast cancer bone metastasisFunctional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cellsIn vitro Cytotoxicity Effects of 197Au/PAMAMG4 and 198Au/PAMAMG4 Nanocomposites Against MCF7 and 4T1 Breast Cancer Cell Lines.Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells.Differential protein occupancy profiling of the mRNA transcriptome.Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors.Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential.Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells.Proteomic snapshot of breast cancer cell cycle: G1/S transition point.Computational analyses of curcuminoid analogs against kinase domain of HER2A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.An ex vivo model to study hormone action in the human breast.Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesisEstrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.Choosing the right cell line for breast cancer researchMCF-7 Human Breast Cancer Cells Form Differentiated Microtissues in Scaffold-Free Hydrogels.A meta-analysis to evaluate the cellular processes regulated by the interactome of endogenous and over-expressed estrogen receptor alpha.Automated Identification of Core Regulatory Genes in Human Gene Regulatory NetworksThe new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slicesBAX/BCL-2 mRNA and protein expression in human breast MCF-7 cells exposed to drug vehicles-methanol and dimethyl sulfoxide (DMSO) for 24 hrs.Genomic antagonism between retinoic acid and estrogen signaling in breast cancer.Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing.Doxorubicin Changes Bax /Bcl-xL Ratio, Caspase-8 and 9 in Breast Cancer Cells.Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy
P2860
Q24607151-E2090CA4-42D7-4C09-B63C-06196329B4CCQ24671914-2EA9CBF3-EB5A-49C0-A800-F12932D11956Q24810367-82873005-53D7-41EA-AF6E-3681B633C232Q26830744-7C7CF72E-91C4-4FDF-A405-3A2F94F5982CQ28298585-A56E1946-5DA7-479B-BBD0-8849AF089775Q28818488-0BFD82C6-BC5E-47AC-A771-F5D7B502D1A3Q30453395-11B18814-999F-458F-BE0A-2DAD860C9249Q30473787-0B21A10B-DB49-4D6D-8AE7-380DEF2020E2Q30828525-F784B731-68AF-4773-A41E-59B6DD262C0FQ33308716-C7C04621-0DF8-4B76-9F91-A099A9A25D69Q33664110-CAA90A85-2C99-48DC-80AC-15D93856980AQ33750907-E554BE01-A448-43CF-AC9C-ED04B2B2FD34Q33751471-224D5D70-0059-491A-81B1-4FF4D75B9A1DQ33814770-0D470534-F295-4AA1-9671-1FC3B22885DCQ33829335-FFE47D02-8C8D-47E1-8613-1713700B5DA5Q33869769-E9B4BF88-9273-4597-9B8A-B218D715002BQ33890864-16E07588-E412-4AD9-BD77-B5647D6F837BQ33966952-B6F0CA66-99AC-4184-8D02-1351F18F13A0Q34010320-2448A127-ED32-4ED9-9FB2-55053BCA6BFAQ34084939-37CCDC9B-6A23-48A0-AF06-FA5B301AC114Q34324699-31039F3F-1221-47EB-B36B-BC286583490AQ34387890-12544FEA-8137-4169-B3D2-FC651D78FBA3Q34674316-8D11071A-2626-4FAD-9CE6-6D29D302B968Q34708926-4EDB651E-CA89-455A-BC08-7F62278C5A0EQ34736075-A9AD8A46-368C-4E5C-ACAD-8BA9243650E4Q35002418-3FB0F09C-546F-4937-9D93-6C977F5595E0Q35161911-FFF7EE90-3255-4D0F-A176-7DC1E8B824AFQ35301052-96875648-332E-428A-8266-1ECCB12E14F5Q35571438-AF57ECD9-CDB9-42B7-9246-E37257F34F41Q35608671-DEC7875F-BF44-4D8F-8E44-74AD1FED7D2DQ35744004-9BD95A43-525E-4B93-BAE6-1EAEC1BEF591Q35745028-A9FE4D91-B891-49F5-BE70-2B135085812DQ35783004-8E1AEFA8-7E84-46DB-ABE9-555381701743Q35827822-0ECD9F75-3F51-4DCB-9B3E-1CDEB252D4CFQ35863759-9CB00D8F-B009-4132-9AF1-3986D9B8E4B8Q35898541-A63C1101-E590-46A8-BC35-E450953BC82BQ36028691-0D839AE3-3856-4FAA-8E2C-F8DDBBB8C3F4Q36160576-CFFA1A98-5285-4829-92D5-EC4FCC457F91Q36196067-B51230F1-FD05-4A6A-9F33-F268A73BB748Q36315850-DCC560B2-7355-44AF-B41B-7E0E2B9A2CAB
P2860
MCF-7: the first hormone-responsive breast cancer cell line.
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
MCF-7: the first hormone-responsive breast cancer cell line.
@ast
MCF-7: the first hormone-responsive breast cancer cell line.
@en
MCF-7: the first hormone-responsive breast cancer cell line.
@nl
type
label
MCF-7: the first hormone-responsive breast cancer cell line.
@ast
MCF-7: the first hormone-responsive breast cancer cell line.
@en
MCF-7: the first hormone-responsive breast cancer cell line.
@nl
prefLabel
MCF-7: the first hormone-responsive breast cancer cell line.
@ast
MCF-7: the first hormone-responsive breast cancer cell line.
@en
MCF-7: the first hormone-responsive breast cancer cell line.
@nl
P1433
P1476
MCF-7: the first hormone-responsive breast cancer cell line.
@en
P2093
A S Levenson
V C Jordan
P304
P407
P577
1997-08-01T00:00:00Z